INBX — Inhibrx Biosciences Inc
NASDAQ · Biotechnology · Biotechnology
- Latest Close
- $115.09
- 30-Day Move
- +40.0%
- Market Cap
- $928M
- Shares Outstanding
- 14,540,000
- P/B Ratio
- 143.75
- ROE
- -1752.2%
Analyst consensus: Sell · 6 analysts
Inhibrx Biosciences Inc
A read-only Alphactor snapshot for Inhibrx Biosciences Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of 2026-04-22
Topline snapshot
Latest Close
$115.09
30-Day Move
+40.0%
Market Cap
$928M
Shares Outstanding
14,540,000
P/B Ratio
143.75
ROE
-1752.2%
$115.09
+40.0%last 90 delayed daily bars
90D High
$155.29
90D Low
$57.30
Avg Volume
252,903
Net margin is -5465.6%, useful for comparing INBX against peers in Biotechnology.
INBX is up 40.0% over the last 30 trading days shown on this page.
Latest operating income is $-31M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$1.63
Rule of 40
-9436.5%
Dark Pool Short %
69.3%
Latest Close
$115.09
30-Day Move
+40.0%
Market Cap
$928M
Shares Outstanding
14,540,000
P/B Ratio
143.75
ROE
-1752.2%
ROA
-95.6%
Operating Margin
-5522.6%
Net Margin
-5465.6%
Debt / Equity
12.58
Current Ratio
3.93
Latest Revenue
$0
Revenue
$0
Gross Profit
--
Operating Income
$-31M
Net Income
$-33M
Gross Margin
--
Net Margin
-546564.0%
Current Ratio
3.93
Debt / Equity
12.58
Fair Value
$1.63
Upside / Downside
-98.6%
Signal
Overvalued
Implied Growth
--
EV/Rev
$1.63
Growth Assumption
0.0%
Discount Rate
10.5%
Terminal Growth
2.0%
Base FCF
--
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Negative FCF — company is cash-flow negative. Reverse DCF requires positive cash flows.
Altman Z
-0.55
Distress
Piotroski
2
Weak (0-3)
Cash Conversion
0.93x
Rule of 40
-9436.5%
Concerning
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $1M | $-115M | $-115M | $-91M |
| 2023-12-31 | $2M | $-219M | $-241M | $-198M |
| 2024-12-31 | $200,000 | $-331M | $1.7B | $-197M |
| 2025-12-31 | $1M | $-135M | $-140M | $-130M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
Buy Value
$0
Sell Value
$11M
Buys
0
Sells
3
Buy Value
$0
Sell Value
$11M
Buy/Sell Ratio
0.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2025-10-07 | VIKING GLOBAL INVESTORS LP | Sell | 25,042 | $32.25 |
| 2025-10-07 | VIKING GLOBAL INVESTORS LP | Sell | 16,315 | $32.25 |
| 2025-10-07 | VIKING GLOBAL INVESTORS LP | Sell | 308,643 | $32.25 |
| 2025-05-28 | MANHARD KIMBERLY | A | 15,000 | $0.00 |
| 2025-05-28 | Vuori Kristiina MD | A | 15,000 | $0.00 |
| 2025-05-28 | Kayyem Jon Faiz | A | 15,000 | $0.00 |
| 2025-05-28 | FORSYTH DOUGLAS | A | 15,000 | $0.00 |
BlackRock
Filed 2024-05-10
$96M
--
Capital Research Global Investors
Filed 2026-02-11
$33M
--
Citadel Advisors
Filed 2026-02-17
$11M
--
Renaissance Technologies
Filed 2026-02-12
$4M
+526.2%
Marshall Wace
Filed 2026-02-13
$2M
--
2.17
Consensus
Sell—
—
—
6
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.